These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30018082)

  • 1. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
    Jenkins C; Luty SB; Maxson JE; Eide CA; Abel ML; Togiai C; Nemecek ER; Bottomly D; McWeeney SK; Wilmot B; Loriaux M; Chang BH; Tyner JW
    Sci Signal; 2018 Jul; 11(539):. PubMed ID: 30018082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.
    Chang BH; Thiel-Klare K; Tyner JW
    bioRxiv; 2024 Jun; ():. PubMed ID: 38798550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
    Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
    Maxson JE; Abel ML; Wang J; Deng X; Reckel S; Luty SB; Sun H; Gorenstein J; Hughes SB; Bottomly D; Wilmot B; McWeeney SK; Radich J; Hantschel O; Middleton RE; Gray NS; Druker BJ; Tyner JW
    Cancer Res; 2016 Jan; 76(1):127-38. PubMed ID: 26677978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
    Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
    Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
    Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.
    Murray HC; Miller K; Brzozowski JS; Kahl RGS; Smith ND; Humphrey SJ; Dun MD; Verrills NM
    Mol Cell Proteomics; 2023 Mar; 22(3):100503. PubMed ID: 36682716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
    Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
    Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
    Gritsman K; Yuzugullu H; Von T; Yan H; Clayton L; Fritsch C; Maira SM; Hollingworth G; Choi C; Khandan T; Paktinat M; Okabe RO; Roberts TM; Zhao JJ
    J Clin Invest; 2014 Apr; 124(4):1794-809. PubMed ID: 24569456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
    Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
    Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
    Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
    Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
    Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
    Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.